The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial with healthy volunteers of a study drug for certain types of cancer and solid tumors. This study will look at the effects of the study drug when taken with another medication.
The study drug is being evaluated for the treatment of specific cancers and solid tumors, such as breast and prostate cancer. Millions of people are diagnosed with these cancers every year. Affected patients need effective and safe treatments, and healthy volunteers are an important part of developing these medicines.
Read more about this study below and see if you can make a difference as a healthy volunteer.
Who may participate
Participants in clinical trials are essential to the discovery of potential new treatments that could help patients around the world.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-65 years
Sex
All sexes
Referral bonus
Up to $225
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
This study consists of 2 distinct groups, called cohorts. The cohort that you are in will determine the exact dosing schedule, but both cohorts follow a similar structure which is summarized below:
If you choose to participate, you will stay at our facility for up to 15 consecutive overnights. The morning after your admission, you will receive a single oral dose of the study drug after breakfast. Then, about 5 days later, you’ll begin receiving doses of an additional medication either once a day or four times daily for the rest of your stay, except for the day that you are scheduled to leave the unit. On the 3rd or 4th day of receiving this medication, you will also receive another single dose of the study drug. All doses of all medications in this study will be provided as tablets or capsules to swallow and may be given with or without food.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
*Some participants may be asked to return to the PCRU for a follow-up visit for additional safety assessments instead of completing a phone call and will receive an additional $400 for this visit.
Required overnight stays
Up to 15 consecutive overnights
Long-term follow up
1 phone call or visit*
How long is this study?
About 45 days
Compensation
Up to $6,850* upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
The PCRU Loyalty Program has arrived!
Our new Loyalty Program offers unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.